🇺🇸 FDA
Patent

US 8486935

Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine

granted A61KA61K31/538A61K45/06

Quick answer

US patent 8486935 (Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/538, A61K45/06, A61P, A61P1/00